Abbott Laboratories Licenses the Rosetta Resolver Gene Expression Data Analysis System.Business Editors & Health/Medical Writers BIOWIRE2K KIRKLAND, Wash.--(BW HealthWire)--March 25, 2002 Rosetta Biosoftware today announced that it licensed the Rosetta Resolver(R) Gene Expression Data Analysis System to Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals and health care company. It has over 65,000 employees and operates in 130 countries. The corporate headquarters are in Abbott Park, Illinois, a neighborhood of North Chicago, Illinois. . The Rosetta Resolver system is an enterprise bioinformatics solution for gene expression research developed by Rosetta Biosoftware and exclusively distributed by Agilent Technologies This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. , Inc. (NYSE NYSE See: New York Stock Exchange :A). The Rosetta Resolver system can be used with a variety of third party and internally developed DNA microarray DNA microarray A small solid support, usually a membrane or glass slide, on which sequences of DNA are fixed in an orderly arrangement. DNA microarrays are used for rapid surveys of the expression of many genes simultaneously, as the sequences contained on a technologies, including Agilent DNA microarrays. "For more than one hundred years, Abbott has focused on advancing medical science and the practice of health care with our expertise in a variety of therapeutic areas," said Don Halbert, director of genomics, bioinformatics, and molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller at Abbott Laboratories. "Our licensing of the Rosetta Resolver system is in line with our efforts to acquire the latest, most effective drug discovery technology solutions to complement our expertise in the discovery and development of highly effective and efficient medicines and therapies." "Abbott Laboratories has an established tradition of scientific progress in areas such as diabetes, pain management, and HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. ," said Douglas E. Bassett, Ph.D., vice president and general manager of Rosetta Biosoftware. "We are pleased to work with Abbott in these and other therapeutic areas, and to ensure that the Rosetta Resolver system continues to be at the cutting edge of drug discovery research software solutions." About the Rosetta Resolver System The Rosetta Resolver system is a high-capacity data storage, retrieval and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets, or compare and analyze large databases of expression profiles. The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce an enterprise solution for rapid analysis of gene expression data. The system can accept and analyze data from a wide variety of expression profiling Microarray technology is often used for gene expression profiling. It makes use of the sequence resources created by the genome sequencing projects and other sequencing efforts to answer the question, formats, including Agilent DNA microarrays, and applies Rosetta Biosoftware's proprietary error models to yield quality statistics for every gene expression measurement. These statistics are automatically leveraged by all analysis tools, ensuring reliable results. In addition to Abbott Laboratories, life science organizations that have licensed the Rosetta Resolver system include many of the top drug development companies in the world, such as Aventis Pharmaceuticals, Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were , GlaxoSmithKline and Merck & Co., Inc., as well as premier academic institutions such as the Harvard University Center for Genomics Research. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com. About Rosetta Biosoftware Rosetta Biosoftware is a leading provider of bioinformatics solutions to aid in drug discovery and the development of pharmaceutical and agricultural products. Its enterprise software solutions, including the Rosetta Resolver Gene Expression Data Analysis System, are designed to accelerate life science research using advanced genomic data analysis technology. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics, Inc., a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Merck & Co., Inc. (NYSE:MRK MRK Merck & Company (stock symbol) MRK Mayer-Rokitansky-Kuster (anomaly) MRK Manual Remote Keying ). For more information on Rosetta Biosoftware, please visit www.rosettabio.com. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global technology leader in communications, electronics and life sciences. The company's 39,000 employees serve customers in more than 120 countries. Agilent had net revenue of $8.4 billion in fiscal year 2001. Information about Agilent is available on the Web at www.agilent.com. About Abbott Laboratories Abbott Laboratories is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceutical, nutritionals, and medical products, including devices and diagnostics. The company employs approximately 70,000 people and markets its products in more than 130 countries. In 2001, the company's sales and net earnings were $16.3 billion and $2.9 billion, respectively, with diluted earnings per share diluted earnings per share An earnings measure calculated by dividing net income less preferred stock dividends for a period by the average number of shares of common stock that would be outstanding if all convertible securities were converted into shares of of $1.88, excluding one-time charges. Abbott 's news releases and other information are available on the company's Web site at www.abbott.com Forward-Looking Statements This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect the businesses of Merck & Co., Inc., including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies and those uncertainties mentioned in the cautionary statements in Item 1 of Merck & Co., Inc.'s Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended Dec. 31, 2000, in Merck & Co., Inc.'s periodic reports on Form 10-Q Form 10-Q See 10-Q. and Form 8-K Form 8-K The form required by the SEC when a publicly held company incurs any event that might affect its financial situation or the share value of its stock. Form 8-K See 8-K. (if any) and referred to under "Cautionary Statement Concerning Forward-Looking Statements" in Merck & Co., Inc.'s Registration Statement on Form S-4 filed May 31, 2001 (as amended), which we incorporate by reference. Resolver is a registered trademark of Rosetta Inpharmatics, Inc. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion